Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Nevada-based Avant Technologies and Ainnova Tech, of Houston, Texas, announced Nov. 20 that the two companies would advance Ainnova’s proprietary low-cost retinal camera packaged with the Vision AI...
Atsena Therapeutics announced Nov. 13 that it had granted exclusive commercial rights for its Leber congenital amaurosis type 1 (LCA1) gene therapy candidate ATSN-101 to Nippon Shinyaku in the US a...
Kalaris Therapeutics announced Nov. 8 that it would merge with biotech company AlloVir in an all-stock transaction to advance Kalaris’ next-generation anti-VEGF candidate TH103 for exudative retina...
Aileron Therapeutics and Advancium Health Network announced Oct. 31 an exclusive option agreement for Advancium to acquire ALRN-6924, a clinical-stage oncology agent developed by Aileron prior to i...
Clearside Biomedical’s Asia-Pacific partner, Arctic Vision, announced Nov. 7 that it had licensed Chinese commercialization rights for ARVN001, marketed in the US as Xipere, to Santen Pharmaceutica...
Ophthalmology remains an appealing investment, driven largely by procedural growth. While hundreds of companies are working toward technology enhancements and innovative therapies, ophthalmology pr...
EyePoint Pharmaceuticals led recent ophthalmic fundraising efforts with a $161 million upsized underwritten public offering. Proceeds in part will fund clinical development of Duravyu. Financing an...
Ben Yerxa, PhD, and George Magrath, MD, say they have a way out of the jungle in which ocular gene therapy development has been trapped since the US FDA approved Luxturna in 2017. “You have to be r...
NovaBay reported Nov. 6 that it had accepted a higher offer from PRN Physician Recommended Nutriceuticals, LLC, which revised its bid for NovaBay’s Avenova product line after a competing overture f...
Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...
NovaBay reported Nov. 6 that it had accepted a higher offer from PRN Physician Recommended Nutriceuticals, LLC, which revised its bid for NovaBay’s Avenova product line after a competing overture f...
Taiwan-based Formosa Pharmaceuticals announced Oct. 31 that it had entered into an exclusive licensing agreement with DÁVI Farmacêutica, of Portugal, for the rights there to market clobetasol propi...
NovaBay reported Oct. 29 that it had received a better offer for its assets than the one it had accepted from PRN Physician Recommended Nutriceuticals, LLC. NovaBay’s board determined that the unso...
South Korean companies GC Biopharma and Novelty Nobility announced Oct. 28 that they would jointly research and develop a novel treatment candidate for geographic atrophy (GA). The companies said a...
Ocuphire Pharma announced Oct. 22 that it would acquire Opus Genetics in an all-stock transaction. The combined company will operate under the Opus name and will trade on the Nasdaq under the ticke...
Barcelona-basedGrifols reported Oct. 22 that it is partnering with the US government’s BARDA to test ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sul...
Orasis Pharmaceuticals announced Oct. 16 that it had licensed its Qlosi presbyopia drops to Optus Pharmaceuticals for the Korean market. Under the deal, Optus will pay upfront and milestone payment...
France’s Nicox announced Oct. 14 a deal with Soleus Capital under which Soleus will acquire Nicox’ royalties from the glaucoma treatment Vyzulta for $15 million, while providing $1.5 million in equ...
Orasis Pharmaceuticals led recent ophthalmic fundraising efforts with $78 million in Series D and structured capital to support the launch of Qlosi drops for presbyopia. Financing announced in the ...
The 2024 Ophthalmology Futures European Forum reviewed the decline in ophthalmic deals in 2024 before offering presenting companies some guidance on how to advance their technology in such an envir...
Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...
NovaBay Pharmaceuticals has agreed to sell its Avenova products to PRN Physician Recommended Nutriceuticals for $9.5 million in cash, the companies announced Sept. 20. The deal is expected to close...
Germany’s Novaliq announced Oct. 2 that the European Commission had approved its dry eye treatment Vevizye (cyclosporine ophthalmic solution) 0.1%. The product is indicated for the treatment of mod...
Surrozen announced Sept. 24 that development partner Boehringer Ingelheim will advance SZN-413, a bi-specific antibody targeting retinal vascular disease. The milestone triggers a $10 million payme...
Nanoscope Therapeutics announced Sept. 30 that it had acquired a license for CatCh optogenetic technology from Max Planck Innovation, the technology transfer arm of the Max Planck Society. Financia...
France’s Nicox announced Sept. 23 that it had signed an exclusive research and license option agreement with Glaukos for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5...
Microsurgical Technology (MST) announced Sept. 17 that it had partnered with Vista Ophthalmics to commercialize Vista’s products—the Vista 1-Step vitrectomy probe and the Vista IS for maintaining t...
Bausch + Lomb is working with Goldman Sachs to explore a sale of the company, the Financial Times reported Sept. 14, with private equity the most likely buyer. The move is being evaluated as a way ...
NovaBay Pharmaceuticals has agreed to sell its Avenova products to PRNPhysician Recommended Nutriceuticals for $9.5 million in cash, the companies announced Sept. 20. The deal is expected to close ...
France’s Nicox announced Sept. 18 that partner Ocumension Therapeutics had received regulatory approval in China to commercialize Nicox’ Zerviate (cetirizine ophthalmic solution) 0.24% for ocular i...
Ripple Therapeutics, of Toronto, Canada, announced Sept. 17 that it had signed a collaboration agreement with AbbVie to develop RTC-620, a fully biodegradable sustained-release intracameral bimatop...
Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...
Finland’s Revenio Group announced Aug. 20 that its iCare subsidiary had assumed ownership of the Dutch artificial intelligence (AI) software company Thirona Retina. iCare had made a minority invest...
Finland’s Revenio Group announced Aug. 20 that its iCare subsidiary had assumed ownership of the Dutch artificial intelligence (AI) software company Thirona Retina. iCare had made a minority invest...
Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...
China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...
Lensar has terminated its collaboration agreement with Swiss company Oertli, according to a filing Aug. 5 with the US Securities and Exchange Commission. The two had been developing the Ally Adapti...
Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...
China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...
Japan’s Santen announced Aug. 6 that it had signed an agreement to license CBT-001, a topical pterygiumtreatment candidate from Cloudbreak Pharma. The deal covers the territories of Japan, South Ko...
Lensar has terminated its collaboration agreement with Swiss company Oertli, according to a filing Aug. 5 with the US Securities and Exchange Commission. The two had been developing the Ally Adapti...
Taiwan-based Formosa Pharmaceuticals announced Aug. 5 that it had agreed to license to Apotex exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inflammation and pain...
Eyenovia, of New York, announced July 30 that it had entered into a collaboration agreement with SGN Nanopharma to develop SGN’s micellar nanoparticle platform-based cyclosporine formulation for us...
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Eyenovia, of New York, announced July 23 that it had entered into a collaboration agreement with Japan’s Senju Pharmaceutical to develop Senju’s corneal epithelial wound healing candidate, SJP-0035...
Ophthalmic deals in Q2-2024 reached over $1.6 billion and involved 19 transactions. This compares with $7.0 billion from 25 transactions in Q2-2023 and $2.0 billion from 17 transactions in Q1-2024....
ANI Pharmaceuticals announced June 24 that it would acquire Alimera Sciences, maker of Iluvien and Yutiq, in a deal worth $381 mil-lion up front. The deal is expected to close in late Q3-2024, the ...
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Eyewear conglomerate EssilorLuxottica announced July 17 that it had agreed to acquire an 80 percent stake in Heidelberg Engineering, a leader in ophthalmic diagnostic imaging. Financial details wer...
Beacon Therapeutics will evaluate Abeona Therapeutics’ patented AAV204 capsid for potential gene therapies for select ophthalmic indications, the companies announced July 11. AAV204, a novel AAV ca...
European ophthalmology chain Clínica Baviera has extended its reach into the UK with the purchase of Optimax. Optimax (Eye Hospitals Group and subsidiaries) operates 19 clinics under the Optimax an...
Johnson & Johnson is the lead investor in a Series A funding round for Stamford, Connecticut-based TecLens, developer of a new crosslinking technology, J&J announced June 21. The technology is inte...
Kane Biotech announced June 25 that I-Med Pharma had licensed its DispersinB biofilm dispersion technology to incorporate into its products to relieve dry eye. It’s the first commercial agreement f...
RevOpsis Therapeutics, of San Carlos, California, announced June 17 that it had entered into a strategic manufacturing partnership with India’s Kemwell Biopharma. The deal aims to accelerate develo...
ANI Pharmaceuticals announced June 24 that it would acquire Alimera Sciences, maker of Iluvien and Yutiq, in a deal worth $381 million up front. The deal is expected to close in late Q3-2024, the c...
Global nonprofit eye bank Eversight announced June 5 a four-year partnership with LighTopTech to improve imaging for eye tissues in clinical and research settings. Eversight will integrate LighTopT...
Opthea led recent ophthalmic fundraising efforts with a $113.2 million placement and entitlement offer, as it continues to advance its wet AMD candidate. Financing announced in the past four weeks ...
Merck, of Rahway, New Jersey, announced May 29 that it was acquiring Eyebiotech Limited (EyeBio) for an upfront payment of $1.3 billion and up to $1.7 billion in future milestone payments. The deal...
Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...
Global nonprofit eye bank Eversight announced June 5 a four-year partnership with LighTopTech to improve imaging for eye tissues in clinical and research settings. Eversight will integrate LighTopT...
Sightpath Medical announced May 30 that it had acquired PennVista, a LASIK services business operating in Pennsylvania, Ohio, West Virginia, Indiana, and Michigan. Financial details were not disclo...
Merck, of Rahway, New Jersey, announced May 29 that it was acquiring Eyebiotech Limited (EyeBio) for an upfront payment of $1.3 billion and up to $1.7 billion in future milestone payments. The deal...
South Korea-based HanAll Biopharma announced May 28 that it had licensed Turn Biotechnologies’ epigenetic reprogramming technology for eye and ear diseases. The company said the deal could be worth...
Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...
Partners Xbrane Biopharma, of Sweden, and Germany’s Stada announced May 10 that they had entered into an exclusive licensing agreement with biosimilar company Valorum Biologics to market their rani...
Artificial intelligence was a prominent topic at the 2024 ARVO meeting. Discussions ranged from using AI in published ophthalmic research to employing it in early detection and monitoring of eye di...
Topcon Healthcare announced April 26 that it had appointed Ali Tafreshi as CEO and president. The company said Tafreshi will lead the company’s focus on “oculomics”—diagnosing not just eye disease ...
Partners Xbrane Biopharma, of Sweden, and Germany’s Stada announced May 10 that they had entered into an exclusive licensing agreement with biosimilar company Valorum Biologics to market their rani...
Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...
Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...
Science Corporation, of Alameda, California, reported April 25 that it had acquiredthe IP and related assets for the Prima retinal implant, developed by Pixium Vision SA, of France. Terms of the de...
Ophthalmic deals in Q1-2024 reached over $2.1 billion and involved 20 transactions. This compares with $2.0 billion from 17 transactions in Q1-2023 and $570 million from 12 transactions in Q4-2023....
US-based private equity firm Warburg Pincus and Appasamy Associates announced April 10 that Warburg had bought a controlling stake in the Indian ophthalmic company. Financial details were not discl...
ABVC BioPharma announced March 26 that it had agreed to license its ophthalmology pipeline, including the vitreous substitute candidate Vitargus, to ForSeeCon Eye. ABVC, of Fremont, California, say...
Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...
Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...
US-based private equity firm Warburg Pincus and Appasamy Associates announced April 10 that Warburg had bought a controlling stake in the Indian ophthalmic company. Financial details were not discl...
Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...
West Point Optical Group, which operates 86 Pearle Vision clinics in 13 states, announced April 3 that it had reached an agreement with Verséa Ophthalmics to offer Verséa’s Biovance and Biovance 3L...
ABVC BioPharma announced March 26 that it had agreed to license its ophthalmology pipeline, including the vitreous substitute candidate Vitargus, to ForSeeCon Eye. ABVC, of Fremont, California, say...
Provectus Biopharmaceuticals announced March 27 that it had entered into an agreement with the University of Miami for an exclusive worldwide license of a photodynamic antimicrobial therapy (PDAT) ...
Nashville, Tennessee-based Harrow reported March 19 that its 2023 revenue was $130.2 million, a 47 percent increase over $88.6 million in 2022. The company generated record quarterly revenue in Q4-...
RVL Pharmaceuticals Inc., of New Jersey, formerly a subsidiary of publicly held RVL Pharmaceuticals plc, is now owned by Athyrium Capital Management after emerging from Chapter 11 bankruptcy procee...
Germany’s VSY Biotechnology launched its Enova Maestro trifocal toric preloaded intraocular lens (IOL) at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting, held Feb. ...
RVL Pharmaceuticals Inc., of New Jersey, formerly a subsidiary of publicly held RVL Pharmaceuticals plc, is now owned by Athyrium Capital Management after emerging from Chapter 11 bankruptcy procee...
Eyenovia and NovaBay Pharmaceuticals announced March 13 the signing of a co-promotion agreement to commercialize their prescription ophthalmic products. Under the agreement, NovaBay will market Eye...
Global nonprofit eye bank Eversight and Emmecell announced Feb. 20 that they would collaborate to advance cell therapies for corneal treatment. Emmecell, of Menlo Park, California, is developing EO...
Swiss drugmaker Sandoz announced Jan. 22 that it had signed an agreement to acquire the US ranibizumab (Lucentis) biosimilar Cimerli from Coherus BioSciences for $170 million up front. The deal inc...
4D Molecular Therapeutics led recent ophthalmic fundraising efforts with a $300 million upsized public offering to continue advancing its retinal gene therapy candidate. Financing announced in the ...
Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...
Harrow reported Feb. 15 that it had licensed to Apotex exclusive marketing and distribution rights to Verkasia and over-the-counter Cationorm Plus in the Canadian market. In addition, Apotex will p...
France’s Nicox announced Feb. 8 that it had signed a deal granting Japanese drug company Kowa exclusive Japanese rights to develop and commercialize Nicox’ NCX 470 (0.1% bimatoprost) eye drop for g...
Seattle-based Omeros reported Feb. 1 that it had changed up its agreement with DRI Healthcare Trust for Omidria royalties. DRI, based in Toronto, Canada, has paid Omeros an additional $115 million ...
Encinitas, California-based Kiora Pharmaceuticals reported Jan. 31 that it had granted Théa Open Innovation exclusive worldwide development and commercialization rights, excluding Asia, to KIO-301 ...
Denmark’s Ascendis Pharma announced Jan. 29 that it had founded Eyconis, a separate company to develop and commercialize its ophthalmic assets globally. The company is launching with a $150 million...
Swiss drugmaker Sandoz announced Jan. 22 that it had signed an agreement to acquire the US ranibizumab (Lucentis) biosimilar Cimerli from Coherus BioSciences for $170 million up front. The deal inc...
Rochester, New York-based Iuvo BioScience, a clinical research organization (CRO) that specializes in ophthalmology, reported Jan. 18 that it had acquired privately held Promedica International, an...
Bayer subsidiary BlueRock Therapeutics announced Jan. 23 that it had exercised its option to license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for primary pho...
Privately held Abpro reported Jan. 22 that it will gain a listing on the Nasdaq through a merger with Atlantic Coastal Acquisition Corp. II, a special purpose acquisition company (SPAC) based in Ne...
Ophthalmic deals in 2023 reached nearly $12.3 billion and included 78 transactions. This compares with $5.7 billion in 2022 and $8.5 billion in 2021. Mergers and acquisitions totaled $8.9 billion; ...
Eyenovia announced Jan. 16 that it had reacquired the rights to pediatric myopia candidate MicroPine in the US and Canada from Bausch + Lomb. The investigational formulation of atropine, intended f...
Carl Zeiss Meditec announced in December that Zeiss had agreed to acquire Netherlands-based Dutch Ophthalmic Research Center (DORC) from investment firm Eurazeo for €985 million ($1.1 billion). Eua...
Japanese drugmaker Astellas made the single largest transaction in the 2023 ophthalmic market when it acquired Iveric Bio for $5.9 billion. The deal was announced April 30 and closed on July 11, wh...
Janssen Pharmaceuticals has purchased from MeiraGTx the remaining rights for development, manufacturing, and commercializa-tion of botaretigene sparoparvovec (bota-vec) for $415 million, MeiraGTx r...
Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...
UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sophi phaco machines are battery-...
Eyenovia announced Jan. 16 that it had reacquired the rights to pediatric myopia candidate MicroPine in the US and Canada from Bausch + Lomb. The investigational formulation of atropine, intended f...
Belgium’s Oxurion announced Dec. 28 that it had avoided bankruptcy through an agreement with its main creditor, Atlas Special Opportunities. Atlas will continue to fund Oxurion under an existing 20...
Nordic Pharma subsidiary Amring Pharmaceuticals announced Dec. 18 that it had completed its acquisition of Visant Medical. Visant received US FDA 510(k) clearance in 2022 for its Lacrifill cross-li...
Janssen Pharmaceuticals has purchased from MeiraGTx the remaining rights for development, manufacturing, and commercialization of botaretigene sparoparvovec (bota-vec) for $415 million, MeiraGTx re...
Privately held Visiox Pharmaceuticals reported Dec. 27 that it will gain a listing on the Nasdaq through a merger with PowerUp Acquisition Corp., a special purpose acquisition company (SPAC) based ...
ECM Therapeutics, of Warrendale, Pennsylvania, reported Dec. 19 that it would collaborate with the Louis J. Fox Center for Vision Restoration on work to restore vision following optic nerve damage....
RetinAI reported Nov. 29 that it had joined a global nonprofit consortium of physicians, researchers, and industry partners working to define optimal biomarkers and endpoints in age-related macular...
Carl Zeiss Meditec announced Dec. 15 that it had agreed to acquire Netherlands-based Dutch Ophthalmic Research Center (DORC) from investment firm Eurazeo, of Paris. DORC, founded in 1983, is a lead...
Seattle-based Kubota Vision reported Dec. 6 that it agreed to provide Aurolab, of India, with an exclusive license to develop, manufacture, and distribute eyeMo, Kubota’s low-cost, home-based, self...
Genentech and Nvidia reported Nov. 21 that the two companies had formed a multi-year strategic research collaboration to accelerate Genentech’s proprietary algorithms and speed drug development. Ge...
Enzene Biosciences, based in Pune, India, announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references...
Genentech and Nvidia reported Nov. 21 that the two companies had formed a multi-year strategic research collaboration to accelerate Genentech’s proprietary algorithms and speed drug development. Ge...
Ophthalmic company Keeler announced Nov. 15 that it had formed a partnership with Long Grove Pharmaceuticals to distribute Ak-fluor (fluorescein injection) for diagnostic fluorescein angiography. L...
Stuart Therapeutics announced Oct. 18 that it had granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a...
Aldeyra Therapeutics announced Nov. 1 that AbbVie had signed an exclusive option agreement to license to develop, manufacture, and commercialize reproxalap, Aldeyra’s candidate in development for d...
Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...
Privately held Lenz Therapeutics announced Nov. 15 that it had entered into an agreement to merge with Nasdaq-listed Graphite Bio in an all-stock transaction. The combined company would take the Le...
Visionix’ US division announced Nov. 10 that it had entered into a strategic alliance with 20/20Now to bring tele-optometry to more optical retailers. 20/20Now, of Holbrook, New York, offers a soft...
Aldeyra Therapeutics announced Nov. 1 that AbbVie had signed an exclusive option agreement to license to develop, manufacture, and commercialize reproxalap, Aldeyra’s candidate in development for d...
Aeye Health and Topcon’s diabetic point-of-care eye exam arm, Topcon Screen, announced Oct. 27 that they would partner to deliver artificial intelligence-aided screening for diabetic retinopathy (D...
Stuart Therapeutics announced Oct. 18 that it had granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a...
Ophthalmic deals in Q3-2023 reached nearly $2.8 billion and involved 22 transactions. This compares with $6.9 billion from 24 transactions in Q2-2023 and $1.0 billion from 20 transactions in Q3-202...
Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...
Canada’s LSL Pharma Group announced Oct. 18 that it had reached a deal with US specialty pharmaceutical company Fera to import erythromycin ophthalmic ointment (5mg/g) for the treatment of newborns...
Spain’s SpliceBio announced Oct. 17 that it had signed an agreement with Spark Therapeutics to utilize SpliceBio’s protein splicing platform to develop a gene therapy for an undisclosed inherited r...
China’s AffaMed Technologies announced Oct. 10 that it had entered into an agreement with SIFI, of Italy, to manufacture, develop, and commercialize SIFI’s Evolux enhanced monofocal intraocular len...
German companies Zeiss and Boehringer Ingelheim reported Oct. 2 that they would collaborate long-termon developing predictive analytics to foster earlier detection of eye disease and more personali...
Israel’s Everads Therapy announced Sept. 27 that it had entered into an agreement with Kriya Therapeutics to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads’ supracho...
Netherlands-based ProQR Therapeutics announced Sept. 27 that a deal with France’s Laboratoires Théa to acquire ProQR’s late-stage ophthalmic assets had been terminated. Théa had agreed in August 20...
London-based CS Pharmaceuticals reported July 28 that it had acquired AxeroVision, of Carlsbad, California, and its AXR-270 candidate for dry eye disease. The company did not report financial detai...
Swiss company Novartis reported Sept. 15 that its shareholders had approved its spinoff of Sandoz, its generics and biosimilars business. The target date for the spinoff is Oct. 4. Sandoz is a lead...
BVI Medical announced Sept. 6 that it had acquired Medical Mix, a leading supplier of ophthalmic surgical devices in Spain and Portugal. No financial details were provided. Medical Mix, of Barcelon...
The US Federal Trade Commission (FTC) will allow Amgen to acquire Horizon Therapeutics, after Amgen agreed in a consent order to several conditions related to how it will market its newly purchased...
Carl Zeiss Meditec announced Aug. 23 that more than 8 million eyes had been treated with the company’s SMILE procedure through the first half of 2023. SMILE, short for small-incision lenticule extr...
NovaBay Pharmaceuticals and BioStem Technologies announced an agreement Sept. 11 under which NovaBay will commercialize BioStem’s ocular amniotic tissue allograft. No financial details for the deal...
Japan’s Otsuka Pharmaceutical and ShapeTX announced Sept. 7 that they would collaborate to develop intravitreally delivered adeno-associated virus (AAV) gene therapy candidates for ocular diseases,...
Link Biologics, of London, and France’s Théa Open Innovation announced Sept. 12 that they had agreed to co-develop Link’s topical anti-inflammatory candidate TSG6 for dry eye disease and other opht...
BVI Medical announced Sept. 6 that it had acquired Medical Mix, a leading supplier of ophthalmic surgical devices in Spain and Portugal. No financial details were provided. Medical Mix, of Barcelon...
The US Federal Trade Commission (FTC) will allow Amgen to acquire Horizon Therapeutics, after Amgen agreed in a consent order to several conditions related to how it will market its newly purchased...
The California Institute for Regenerative Medicine (CIRM) announced July 27 that it had awarded a $12.4 million grant to Regenerative Patch Technologies (RPT) to support a Phase IIb clinical trial ...
Iridex announced Aug. 29 that it would undergo a review of strategic alternatives, with Piper Sandler acting as financial advisor for the process. The Mountain View, California, ophthalmic laser co...
Nancy Lurker, executive vice chair of EyePoint Pharmaceuticals, sat with Market Scope at the 2023 meeting of the American Society of Retina Specialists (ASRS) and reflected on the challenges of run...
Netherlands-based ProQR Therapeutics announced Aug. 1 that France’s Laboratoires Théa would acquire ProQR’s late-stage ophthalmic assets, sepofarsen and ultevursen, targeting inherited retinal dise...
New York’s Icahn School of Medicine at Mount Sinai announced July 5 that it had launched the Center for Ophthalmic Artificial Intelligence and Human Health. The center will incorporate AI into educ...
Taiwan-based Formosa Pharmaceuticals announced Aug. 16 that Eyenovia had licensed US rights to Formosa’s APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) for inflammation and pain ...
Netherlands-based ProQR Therapeutics announced Aug. 1 that France’s Laboratoires Théa would acquire ProQR’s late-stage ophthalmic assets, sepofarsen and ultevursen, targeting inherited retinal dise...
Harrow announced July 31 that the transfer of rights to Vigamox from Novartis was complete and it had launched sales of the antibiotic eye drop in the US. Vigamox (moxifloxacin hydrochloride ophtha...
Celularity and Verséa Ophthalmics announced an exclusive US commercial agreement on July 27. Verséa will distribute Celularity’s Biovance and Biovance 3L for ocular surface disease and ocular surgi...
Sweden’s Xbrane Biopharma and its partner Stada, of Germany, announced July 24 that they were looking for a new partner to commercialize their ranibizumab biosimilar in the US and Canada, after the...
Ophthalmic deals in Q2-2023 surpassed $6.9 billion and involved 24 transactions. This compares with $1.8 billion from 16 transactions in Q1-2023 and $1.7 billion from 23 transactions in Q2-2022. Pu...
Brent Saunders seems to be betting that what was good for Allergan’s eye care business will be good for Bausch + Lomb. Dry eye treatments dominated Allergan’s eye care business during Saunders’ ten...
Japan’s Astellas Pharma and 4D Molecular Therapeutics announced July 10 that Astellas is licensing 4DMT’s R100 intravitreal gene therapy vector for one rare inherited ophthalmic disease, with optio...
Japanese drugmaker Santen announced July 18 that Harrow had acquired US or Canadian commercial rights to seven of Santen’s branded eye drops, while Visiox Pharma had licensed US rights to Omlonti f...
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.